HADLIMA™ (adalimumab-bwwd) injection, 40 mg/0.4 mL & 40 mg/0.8 mL is now interchangeable with all high- and low-concentration presentations ...

HADLIMA™ (adalimumab-bwwd) injection, 40 mg/0.4 mL & 40 mg/0.8 mL is now interchangeable with all high- and low-concentration presentations (autoinjector, prefilled syringe, and single-dose vial) of ...

Uppsala University Hospital was the first in Europe to initiate an academic CAR T study for patients with B-cell lymphoma. Five years later, in 2019, the first patient was treated within standard ...

Tandem-target CAR-T produced a response in all participants with relapsed or refractory mantle cell lymphoma in a phase 1/2 study. Patients received their CAR-T within 8 to 12 days of lymphodepletion.

Anaplastic large cell lymphoma (ALCL) belongs to the subgroup of non-Hodgkin's lymphomas and is a rare but aggressive form of T-cell lymphoma that usually occurs in children and young adults.

Anaplastic large cell lymphoma (ALCL) belongs to the subgroup of non-Hodgkin's lymphomas and is a rare but aggressive form of T-cell lymphoma that usually occurs in children and young adults.

Notably, this patient had previously undergone 7 prior lines of therapy including chemoimmunotherapies, CD19 CAR T cells ... and refractory B-cell non-Hodgkin's lymphoma (B-NHL; NCT05370430 ...

The studies span breast cancer and other solid tumors (glioblastoma, endometrial cancer, lung cancer, gastric cancer), as well as multiple blood cancers (multiple myeloma, large B-cell lymphoma ...

The most advanced Galapagos cell therapy program is GLPG5101. Though Galapagos generated encouraging early clinical data for this therapy in non-Hodgkin lymphoma ... its CAR T-platform alone ...

We simply can’t explain why Eric’s line was transferred after he gave a verbal no. Disheartening, but there is an extra protection for your cell number, no matter what carrier you use.